Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982448 | 0.87 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL4462435 | 0.83 | KMT2A (0.61) | SMN1; SMN2ALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL7454384 | 0.80 | LRRK2 (0.49) | ALDH1A1KDM4EKMT2AL3MBTL1LRRK2 | |
| SCHEMBL2028545 | 0.76 | TSHR (0.47) | KMT2AMEN1MAPT | |
| SCHEMBL2378215 | 0.74 | KMT2A (0.75) | SMN1; SMN2ALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL12312156 | 0.73 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL29833145 | 0.73 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL4270753 | 0.73 | SLC6A5 (0.62) | SMN1; SMN2ALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL16406345 | 0.73 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4EGAAL3MBTL1 | |
| SCHEMBL14994813 | 0.72 | KDM4E (0.59) | SMN1; SMN2ALDH1A1KDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3075730-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2785699-B1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3075730-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-10-05 | — | — | EP | disclosed |
| EP-2576541-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| EP-2785699-A1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8809331-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8802674-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130157999-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013079494-A1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-20130096102-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2576541-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011151360-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096102-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, P2RX6 | SMN1; SMN2 212/4885ALDH1A1 2090/4885KDM4E 2542/4885 |
| US-20130157999-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, P2RX6 | SMN1; SMN2 401/4885ALDH1A1 1987/4885KDM4E 2135/4885 |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, PKN2 | SMN1; SMN2 211/4885ALDH1A1 1864/4885KDM4E 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.